0001415889-24-017635.txt : 20240620 0001415889-24-017635.hdr.sgml : 20240620 20240620162422 ACCESSION NUMBER: 0001415889-24-017635 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240618 FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fischer Seth H. Z. CENTRAL INDEX KEY: 0001573553 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36576 FILM NUMBER: 241056595 MAIL ADDRESS: STREET 1: C/O TRIUS THERAPEUTICS, INC. STREET 2: 6310 NANCY RIDGE DRIVE, SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Fischer Seth H.Z. DATE OF NAME CHANGE: 20130402 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MARINUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001267813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: 484-801-4670 MAIL ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: MARINUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031022 4 1 form4-06202024_080618.xml X0508 4 2024-06-18 0001267813 MARINUS PHARMACEUTICALS, INC. MRNS 0001573553 Fischer Seth H. Z. 5 RADNOR CORPORATE CENTER, SUITE 500 100 MATSONFORD RD RADNOR PA 19087 true false false false 0 Common Stock 2024-06-18 4 A 0 2300 0 A 12926 D Stock Option (Right to Buy) 1.40 2024-06-18 4 A 0 10450 0 A 2034-06-18 Common Stock 10450 10450 D Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer. /s/ Debra A. Mohollen, Attorney-in-Fact 2024-06-20